Background: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients.
Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the management of ITP.
Methods: In 2015, ASH formed a multidisciplinary guideline panel that included 8 adult clinical experts, 5 pediatric clinical experts, 2 methodologists with expertise in ITP, and 2 patient representatives. The panel was balanced to minimize potential bias from conflicts of interest. The panel reviewed the ASH 2011 guideline recommendations and prioritized questions. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence (up to May 2017) and formulate recommendations.
Results: The panel agreed on 21 recommendations covering management of ITP in adults and children with newly diagnosed, persistent, and chronic disease refractory to first-line therapy who have non-life-threatening bleeding. Management approaches included: observation, corticosteroids, IV immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists.
Conclusions: There was a lack of evidence to support strong recommendations for various management approaches. In general, strategies that avoided medication side effects were favored. A large focus was placed on shared decision-making, especially with regard to second-line therapy. Future research should apply standard corticosteroid-dosing regimens, report patient-reported outcomes, and include cost-analysis evaluations.
© 2019 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: All authors were members of the guideline panel or members of the systematic review team or both. As such, they completed disclosure-of-interest forms, which were reviewed by ASH and are available as supplemental Files 2 and 3.
American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.Blood Adv. 2018 Nov 27;2(22):3292-3316. doi: 10.1182/bloodadvances.2018024786. Blood Adv. 2018. PMID: 30482766 Free PMC article.
American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.Blood Adv. 2019 Dec 10;3(23):3867-3897. doi: 10.1182/bloodadvances.2019000916. Blood Adv. 2019. PMID: 31794601 Free PMC article.
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.Blood Adv. 2018 Nov 27;2(22):3257-3291. doi: 10.1182/bloodadvances.2018024893. Blood Adv. 2018. PMID: 30482765 Free PMC article.
ITP and international guidelines: what do we know, what do we need?Presse Med. 2014 Apr;43(4 Pt 2):e61-7. doi: 10.1016/j.lpm.2014.02.004. Epub 2014 Mar 20. Presse Med. 2014. PMID: 24656296 Review.
Treatment of immune thrombocytopenic purpura in children : current concepts.Paediatr Drugs. 2005;7(5):325-36. doi: 10.2165/00148581-200507050-00004. Paediatr Drugs. 2005. PMID: 16220997 Review.
Cited by 2 articles
Taking Stock of Hemophilia, Immune Thrombocytopenia, and Bone Marrow Failure.Indian J Pediatr. 2020 Feb;87(2):132-133. doi: 10.1007/s12098-019-03165-2. Epub 2020 Jan 3. Indian J Pediatr. 2020. PMID: 31900847 No abstract available.
A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia.Blood Adv. 2020 Jan 14;4(1):9-18. doi: 10.1182/bloodadvances.2019000868. Blood Adv. 2020. PMID: 31891657 Free PMC article.